Pfizer points to drug shortages until mid-2024 as a result of tornado damage to North Carolina plantnews2023-09-25T18:28:06+00:00September 25th, 2023|Endpoints News|
Klick Health rolls out AI for pharma with first industry ChatGPT add-on toolnews2023-09-25T17:28:26+00:00September 25th, 2023|Endpoints News|
Novartis spotlights psoriatic arthritis and Cosentyx with award-winning chef and restaurant ownernews2023-09-25T17:08:06+00:00September 25th, 2023|Endpoints News|
For decades, cancer drug developers have focused on inhibition. Now, a GV-backed startup is eyeing activationnews2023-09-25T15:24:17+00:00September 25th, 2023|Endpoints News|
Antios reportedly shut down; Clene’s long-term ALS data; Keytruda, Lenvima’s lung cancer failuresnews2023-09-25T15:20:24+00:00September 25th, 2023|Endpoints News|
Scynexis pulls vaginal infection tablet from shelves, pauses ongoing trials on the heels of contamination risk concernsnews2023-09-25T15:07:37+00:00September 25th, 2023|Endpoints News|
BridgeBio inks $250M PIPE two months after PhIII heart pill winnews2023-09-25T14:48:58+00:00September 25th, 2023|Endpoints News|
Novartis radioligand triumphs in a first-line PhIII trial recruiting patients with rare neuroendocrine tumorsnews2023-09-25T14:23:41+00:00September 25th, 2023|Endpoints News|
Novo Nordisk’s latest deal with Valo Health aims to boost its cardiometabolic positionnews2023-09-25T14:20:11+00:00September 25th, 2023|Endpoints News|
FDA picks apart BrainStorm’s potential ALS treatment ahead of Wednesday adcommnews2023-09-25T13:53:10+00:00September 25th, 2023|Endpoints News|
